Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MISTHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
MIST stock chart
Technical analysisKey statistics
All statistics- Market cap
- $88.66M
- EPS (TTM)
- -$0.68
- Dividend yield
- None
- 52-week range
- 0.709 – 3.06
- Day range
- 0.7096 – 0.769
- Volume / Avg
- 1.37M / 1.40M
- Beta
- —
- Shares outstanding
- 124.50M
52-week range
MIST stock today
Shares of Milestone Pharmaceuticals (MIST) finished lower on Oct 8 at $0.7121, a drop of 5.96% or $0.0451 per share, versus the S&P 500's 0.47% decline. Shares are 76.7% below their 52-week high of $3.06, set on Dec 12, 2025 and 0.4% above the 52-week low of $0.709, near the bottom of the past year's range. MIST is down 64.7% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 64.4%.
Milestone Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.68), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Milestone Pharmaceuticals
Company profileMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR).
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Joseph G. Oliveto M.B.A.
- Headquarters
- Montreal, QC
- Employees
- 38
- IPO year
- 2019
- Website
- milestonepharma.com
Analyst forecast
ForecastConsensus (7 analysts)
none
Avg. price target
$5.86+722.92%
- Strong buy 1
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
MIST news
All MIST newsMilestone Pharmaceuticals peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ICCCImmuCell Corporation | 9.75 | +0.62% | $88.55M | vs MIST |
| NMRANeumora Therapeutics Inc. | 0.4798 | +2.46% | $90.15M | vs MIST |
| RLYBRallybio Corporation | 16.99 | +0.35% | $90.26M | vs MIST |
| EQEquillium Inc. | 1.44 | +3.60% | $91.31M | vs MIST |
| CGTXCognition Therapeutics Inc. | 0.8952 | -4.42% | $85.13M | vs MIST |
| NRXSNeuraxis Inc. | 6.77 | -0.88% | $85.02M | vs MIST |
| ATRAAtara Biotherapeutics Inc. | 9.23 | -1.49% | $92.65M | vs MIST |
| TELOTelomir Pharmaceuticals Inc. | 1.15 | +2.68% | $84.66M | vs MIST |
Indexes, lists and sector
Appears in lists
Milestone Pharmaceuticals stock FAQ
What is Milestone Pharmaceuticals's stock price today?
MIST last traded at $0.7121 as of Oct 8, 4:00 PM EDT, down 5.96% on the day. Prices are delayed at least 15 minutes.
Who is Milestone Pharmaceuticals's CEO?
Mr. Joseph G. Oliveto M.B.A. is the chief executive officer of Milestone Pharmaceuticals Inc., which has about 38 employees.
What is the MIST 52-week high?
The 52-week high for MIST is $3.06 and the 52-week low is $0.709. The stock is currently 76.7% below its high.